Recce Pharmaceuticals Ltd (ASX: RCE) focuses on synthetic antibiotics to combat antibiotic resistance. The company is founded by Dr. Graham Melrose, a former Executive Director at Johnson & Johnson Australasia and boasts extensive polymer chemistry expertise. Their hydrophilic polymer is both stable and safe, fully soluble across pH levels, even in the acidic stomach environment. It demonstrates rapid efficacy against a broad spectrum of pathogens, including ESKAPE bacteria, with potential for single-dose treatment.
Remarkably, this technology does not promote antibiotic resistance, a crucial advantage in the fight against Antimicrobial Resistance (AMR). The company explores various administration methods, especially for challenging AMR-related indications. With multiple clinical development projects, Recce Pharmaceuticals differentiates itself from existing alternatives. Their intellectual property is protected until 2041, ensuring long-term exclusivity. A planned US Investigational New Drug (IND) application demonstrates their commitment to expanding and establishing a stronger presence in the United States.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 20, 2024
Nov 20, 2024
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
